Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
306.4 INR | +5.06% | +17.10% | +22.73% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Sales 2024 * | 145B 1.74B | Sales 2025 * | 166B 1.99B | Capitalization | 366B 4.39B |
---|---|---|---|---|---|
Net income 2024 * | 9.49B 114M | Net income 2025 * | 9.3B 111M | EV / Sales 2024 * | 3.48 x |
Net Debt 2024 * | 139B 1.67B | Net Debt 2025 * | 143B 1.71B | EV / Sales 2025 * | 3.07 x |
P/E ratio 2024 * |
38.5
x | P/E ratio 2025 * |
42.9
x | Employees | 16,545 |
Yield 2024 * |
0.43% | Yield 2025 * |
0.47% | Free-Float | 37.3% |
Latest transcript on Biocon Limited
1 day | +5.06% | ||
1 week | +17.10% | ||
Current month | +15.99% | ||
1 month | +18.90% | ||
3 months | +18.44% | ||
6 months | +37.96% | ||
Current year | +22.73% |
Managers | Title | Age | Since |
---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 13-04-30 |
Peter Bains
CEO | Chief Executive Officer | 65 | 22-12-11 |
Chairman | 71 | 78-11-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 78-11-28 | |
Director/Board Member | 69 | 99-12-31 | |
Director/Board Member | 60 | 18-07-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.17% | 6 M€ | +6.07% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 306.4 | +5.06% | 45,364,970 |
24-04-25 | 291.6 | +0.71% | 7,923,803 |
24-04-24 | 289.6 | +3.37% | 24,783,740 |
24-04-23 | 280.2 | +3.32% | 10,392,190 |
24-04-22 | 271.2 | +3.63% | 8,601,670 |
Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.73% | 4.18B | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- BIOCON Stock